Roche introduces cobas Respiratory flex test to use its TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses: Basel Wednesday, September 25, 2024, ...

Outbreaks of diseases such as malaria, Zika, and dengue fever underscore the need for efficient diagnostic systems to curb the spread of infectious ... including immunoassays, molecular diagnostics, ...

The Global Infectious Disease Therapeutics Market is projected to grow at a CAGR of 5% from 2024 to 2030, according to a new report ...

The Temperature-Activated Generation of Signal (TAGS) technology was developed by Roche for its high-throughput PCR-based instruments.

Roche argued that its obesity medications would prove to have advantages over its rivals’ — and that the demand for weight ...

Work could lead to the discovery of new therapeutic targets. For the first time, researchers have identified "molecular ...

The CDK7 inhibitors market is anticipated to experience substantial growth in the coming years. This growth is driven by a rise in cancer diagnoses, promising results from early-phase clinical trials ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

These scaffolds act as molecular blueprints, enabling the assembly of diverse molecules into 2D structures without the need ...